In addition, the levels of MCP-1/CCL2 in the influenza virus-infected (pH1N1/OVA or pH1N1/PBS) ZAN-treated mice on Day 3 post-infection were significantly lower than those in infected mice that were not treated with ZAN, again, irrespective of OVA challenge; however, levels in OVA-challenged mice not infected with influenza virus (Mock/OVA) were not affected by ZAN treatment (Fig 6C). The gene discussed is CCL2; the disease is infection.